NK Cell Activation via GM-CSF Antigen Conjugate for Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and enhancing natural killer (NK) cell-mediated immune responses are limited in effectively activating NK cells for cancer treatment, particularly in assessing candidate suitability for additional therapies and measuring therapeutic responses.
Innovation Solution
The method involves isolating peripheral blood mononuclear cells (PBMCs), exposing them to a protein conjugate of granulocyte macrophage colony-stimulating factor (GM-CSF) covalently linked to tumor-associated antigens or oncogene products, activating NK cells, and administering the activated PBMCs to induce a cytotoxic immune response, with repeated assessments to determine treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to detect NK cell activity, then measurement can be performed, but the ability to effectively assess candidate suitability for additional therapies and measure therapeutic responses is limited
Solution Approach 1:
The patent changes the measurement parameter from standard NK cell cytotoxicity assays to a specific flow cytometry-based method measuring CD107a surface expression on NK cells. This parameter change enables both precise measurement of NK cell degranulation activity and assessment of therapeutic response to sipuleucel-T, resolving the contradiction between measurement precision and adaptability to therapy evaluation
2Reliability
If NK cells are activated using conventional methods, then some cytotoxic response is produced, but the cytotoxic cellular response is not sufficiently higher than unactivated PBMCs
Solution Approach 1:
The patent introduces sipuleucel-T as an intermediary substance that mediates NK cell activation. This recombinant protein consisting of human prostatic acid phosphatase fused to GM-CSF acts as a specific activator that produces a significantly higher cytotoxic response compared to conventional activation methods, resolving the contradiction between reliability and productivity of NK cell response
3Difficulty of detecting and measuring
If CD336 is used as a marker of NK cell activation, then cell activation can be identified, but the hallmark NK functionality of lysing target cells cannot be fully assessed
Solution Approach 1:
The patent merges two detection approaches: using CD107a surface expression (analogous to CD336) as an easy-to-detect marker of NK cell activation, combined with a flow cytometry-based assay that simultaneously measures functional cytotoxic activity. This combination resolves the contradiction by providing both ease of detection and functional measurement precision in a single methodology
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to the discovery of novel methods of inducing a natural killer (NK) cell-mediated immune response and increasing NK activity in a mammal for the treatment of tumors and virus infections. The method comprises the steps of isolating peripheral blood mononuclear cells (PBMCs) from the subject, exposing the PBMCs in vitro to protein conjugate comprising granulocyte macrophage colony stimulating factor (GM-CSF) covalently linked to a soluble peptide antigen, under conditions effective to activate the PBMCs, and administering the activated PBMCs to the subject. The invention also relates to a method of detecting in a subject a cytotoxic NK cell-meditated immune response or NK cell activity in vitro by CD336 expression and/or lysis of the K562 tumor line. The invention further relates to a method for determining whether a subject has had a therapeutically effective response to a protein conjugate by assessing the NK activity of activated PBMCs from the subject.